Presentation is loading. Please wait.

Presentation is loading. Please wait.

(A–F) Examples of differences in immune checkpoint inhibition-related colitis. (A–F) Examples of differences in immune checkpoint inhibition-related colitis.

Published byWidya Pranoto Modified over 6 years ago

Similar presentations

Presentation on theme: "(A–F) Examples of differences in immune checkpoint inhibition-related colitis. (A–F) Examples of differences in immune checkpoint inhibition-related colitis."— Presentation transcript:

1 (A–F) Examples of differences in immune checkpoint inhibition-related colitis.
(A–F) Examples of differences in immune checkpoint inhibition-related colitis. Figure parts A and B show two different patients with grade 2 diarrhoea. Figure part A shows no abnormalities on colonoscopy. Figure part B shows a swollen, erosive and friable mucosa. Figure parts C and B show two different patients with grade 3 diarrhoea. Figure part C shows no abnormalities on colonoscopy. Figure part D shows a deeply red colon where the vascular pattern is partially absent, the mucosa appears severely friable and multiple ulcers can be seen. Figure parts E and F show a single patient with grade 1 diarrhoea. During colonoscopy, the entire descending colon (E) showed no abnormalties, while the ascending colon (F) showed a swollen, severely friable mucosa, with deep ulcers. Marnix H Geukes Foppen et al. ESMO Open 2018;3:e000278 Copyright © European Society for Medical Oncology. All rights reserved.

Download ppt "(A–F) Examples of differences in immune checkpoint inhibition-related colitis. (A–F) Examples of differences in immune checkpoint inhibition-related colitis."

Similar presentations

Ulcerative colitis. This image from the colon shows edematous and inflamed mucosa indicative of severe inflammation. Although this patient has ulcerative.

Ulcerative colitis. This image from the colon shows edematous and inflamed mucosa indicative of severe inflammation. Although this patient has ulcerative.
Ulcerative colitis. White exudate is present overlying an abnormal colonic mucosa that has lost its typical vascular pattern. Source: Gastrointestinal.

Ulcerative colitis. White exudate is present overlying an abnormal colonic mucosa that has lost its typical vascular pattern. Source: Gastrointestinal.
Representative hematoxylin-eosin stained (HE) sections demonstrating immune checkpoint inhibition-related colitis representative HE sections demonstrating.

Representative hematoxylin-eosin stained (HE) sections demonstrating immune checkpoint inhibition-related colitis representative HE sections demonstrating.
The publication gap in years for the cumulative percent of cited research papers in the ESMO and the UK overall cancer clinical guidelines, with the difference.

The publication gap in years for the cumulative percent of cited research papers in the ESMO and the UK overall cancer clinical guidelines, with the difference.
Male patients with non-small cell lung cancer (NSCLC) have a 24% reduction in the risk of disease progression (A). Male patients with non-small cell lung.

Male patients with non-small cell lung cancer (NSCLC) have a 24% reduction in the risk of disease progression (A). Male patients with non-small cell lung.
(A) Frequency of synchronous diagnosis of primary tumour and BM according to primary tumour type (B) Frequency of patients with asymptomatic BM at first.

(A) Frequency of synchronous diagnosis of primary tumour and BM according to primary tumour type (B) Frequency of patients with asymptomatic BM at first.
Progesterone receptor nuclear morphology patterns in breast cancer.

Progesterone receptor nuclear morphology patterns in breast cancer.
Invasion front (pushing margin) of the patient's tumour from the primary resection showing a high number of tumour-infiltrating leucocytes, which is characteristic.

Invasion front (pushing margin) of the patient's tumour from the primary resection showing a high number of tumour-infiltrating leucocytes, which is characteristic.
Brain MRI scans for the patient.

Brain MRI scans for the patient.
Recurrence pattern after initial treatment of brain metastases and cause of death. Recurrence pattern after initial treatment of brain metastases and cause.

Recurrence pattern after initial treatment of brain metastases and cause of death. Recurrence pattern after initial treatment of brain metastases and cause.
Meta-analysis of randomised phase III clinical trials with ALK inhibitors in non-small cell lung cancer (NSCLC) showing similar benefit in male patients.

Meta-analysis of randomised phase III clinical trials with ALK inhibitors in non-small cell lung cancer (NSCLC) showing similar benefit in male patients.
Flow chart of the used methodology adapted from Moher et al

Flow chart of the used methodology adapted from Moher et al
The decision tree with the two alternatives.

The decision tree with the two alternatives.
Choice of the study design (superiority vs non-inferiority design) for postregistration trials comparing different treatments for the same therapeutic.

Choice of the study design (superiority vs non-inferiority design) for postregistration trials comparing different treatments for the same therapeutic.
(A) Safety profile overview.

(A) Safety profile overview.
Detection rate for EGFR mutations in cfDNA.

Detection rate for EGFR mutations in cfDNA.
Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.
The 10-year cumulative incidence of CRC death or death due to other causes in patients treated with adjuvant chemotherapy after surgery for stages II–III.

The 10-year cumulative incidence of CRC death or death due to other causes in patients treated with adjuvant chemotherapy after surgery for stages II–III.
The intrinsic apoptotic pathway is a balance between proapoptotic proteins, for example, Bax and Bak and antiapoptotic proteins. The intrinsic apoptotic.

The intrinsic apoptotic pathway is a balance between proapoptotic proteins, for example, Bax and Bak and antiapoptotic proteins. The intrinsic apoptotic.
Methods distribution among the three EQAs

Methods distribution among the three EQAs

Similar presentations

Ads by Google